Login
$PRME
$4.23 +$0.04 (0.97%) After hours

$PRME SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13D/A
13 Nov 2026 SCHEDULE 13G
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition
12 Nov 2026 8-K: Entry into a Material Definitive Agreement

As Representatives of the several Underwriters listed in Schedule 1 hereto

12 Nov 2026 424B5
10 Nov 2026 424B5
10 Nov 2026 8-K: Results of Operations and Financial Condition; Other Events

1 Delivering on the promise of Prime Editing Corporate Presentation November 2026

06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 --

08 Jul 2026 8-K: Other Events

On July 6, 2026, Prime Medicine, Inc. (the "Company") received a final award (the "Final Award") from the arbitration tribunal (the "Tribunal") in the Company's binding arbitration proceedings with Beam Therapeutics, Inc. ("Beam") regard...

08 Jun 2026 Form 4: Schenkein David P, Director

Granted 75,000 Stock Option (right to buy)

08 Jun 2026 Form 4: Marrazzo Jeffrey D, Director

Granted 75,000 Stock Option (right to buy)

08 Jun 2026 Form 4: Nelsen Robert, Director

Granted 75,000 Stock Option (right to buy)

08 Jun 2026 Form 4: Kelly Michael Aaron, Director

Granted 75,000 Stock Option (right to buy)

08 Jun 2026 Form 4: Foster-Cheek Kaye I, Director

Granted 75,000 Stock Option (right to buy)

08 Jun 2026 Form 4: Chung Wendy, Director

Granted 75,000 Stock Option (right to buy)

08 Jun 2026 Form 4: Cahill Thomas, Director

Granted 75,000 Stock Option (right to buy)

08 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 5, 2026, Prime Medicine, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) in a virtual meeting format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy sta...

07 May 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support